Pathology: es-BC - HER2 positive - (neo)adjuvant (NA); la/mBC - HER2 positive - 1st Line (L1); la/mBC - HER2 positive - 2nd Line (L2);
| es-BC - HER2 positive - (neo)adjuvant (NA) | la/mBC - HER2 positive - 1st Line (L1) | la/mBC - HER2 positive - 2nd Line (L2) | ||||||||||||
| GeparQuinto, 2012 | PERTAIN, 2018 | CLEOPATRA, 2012 | PUFFIN, 2020 | SYSUCC-002, 2022 | LUX-Breast 1, 2016 | WJOG6110B/ELTOP, 2018 | EGF104900, 2010 | ExteNET, 2016 | NALA (brain metastases), 2020 | NALA, 2020 | HER2CLIMB (patients with brain metastases), 2020 | HER2CLIMB, 2020 | ||
| neratinib plus capecitabine | 2 | T1 | T1 | |||||||||||
| tucatinib plus trastuzumab plus capecitabine | 2 | T1 | T1 | |||||||||||
| pertuzumab plus trastuzumab plus docetaxel | 2 | T1 | T1 | |||||||||||
| trastuzumab plus endocrine therapy | 1 | T1 | ||||||||||||
| lapatinib plus capecitabine | 1 | T1 | T0 | T0 | ||||||||||
| pertuzumab plus trastuzumab | 1 | T1 | ||||||||||||
| afatinib plus vinorelbine | 1 | T1 | ||||||||||||
| neratinib | 1 | T1 | ||||||||||||
| trastuzumab plus epirubicin and cyclophosphamide followed by docetaxel | 1 | T1 | ||||||||||||
| lapatinib plus trastuzumab | 1 | T1 | ||||||||||||
| trastuzumab plus chemotherapy | 0 | T0 | ||||||||||||
| trastuzumab plus capecitabine | 0 | T0 | T0 | T0 | ||||||||||
| trastuzumab | 0 | T0 | ||||||||||||
| trastuzumab plus docetaxel | 0 | T0 | T0 | |||||||||||
| trastuzumab plus vinorelbine | 0 | T0 | ||||||||||||
| placebo | 0 | T0 | ||||||||||||
| lapatinib plus epirubicin and cyclophosphamide followed by docetaxel | 0 | T0 | ||||||||||||
| lapatinib | 0 | T0 | ||||||||||||